Structural basis for efficient phosphorylation of 3'-azidothymidine monophosphate by Escherichia coli thymidylate kinase. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Structural basis for efficient phosphorylation of 3'-azidothymidine monophosphate by Escherichia coli thymidylate kinase.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14045-50. Unique Identifier : AIDSLINE PDB/5TMP
Lavie A; Ostermann N; Brundiers R; Goody RS; Reinstein J; Konrad M; Schlichting I; Department of Physical Biochemistry, Max Planck Institute for; Molecular Physiology, Rheinlanddamm 201, 44139 Dortmund, Germany.


Abstract: The crystal structures of Escherichia coli thymidylate kinase (TmpK) in complex with P1-(5'-adenosyl)-P5-(5'-thymidyl)pentaphosphate and P1-(5'-adenosyl)P5-[5'-(3'-azido-3'-deoxythymidine)] pentaphosphate have been solved to 2.0-A and 2.2-A resolution, respectively. The overall structure of the bacterial TmpK is very similar to that of yeast TmpK. In contrast to the human and yeast TmpKs, which phosphorylate 3'-azido-3'-deoxythymidine 5'-monophosphate (AZT-MP) at a 200-fold reduced turnover number (kcat) in comparison to the physiological substrate dTMP, reduction of kcat is only 2-fold for the bacterial enzyme. The different kinetic properties toward AZT-MP between the eukaryotic TmpKs and E. coli TmpK can be rationalized by the different ways in which these enzymes stabilize the presumed transition state and the different manner in which a carboxylic acid side chain in the P loop interacts with the deoxyribose of the monophosphate. Yeast TmpK interacts with the 3'-hydroxyl of dTMP through Asp-14 of the P loop in a bidentate manner: binding of AZT-MP results in a shift of the P loop to accommodate the larger substituent. In E. coli TmpK, the corresponding residue is Glu-12, and it interacts in a side-on fashion with the 3'-hydroxyl of dTMP. This different mode of interaction between the P loop carboxylic acid with the 3' substituent of the monophosphate deoxyribose allows the accommodation of an azido group in the case of the E. coli enzyme without significant P loop movement. In addition, although the yeast enzyme uses Arg-15 (a glycine in E. coli) to stabilize the transition state, E. coli seems to use Arg-153 from a region termed Lid instead. Thus, the binding of AZT-MP to the yeast TmpK results in the shift of a catalytic residue, which is not the case for the bacterial kinase.
Keywords: JOURNAL ARTICLE Amino Acid Sequence Antiviral Agents/*METABOLISM Catalytic Domain Crystallography, X-Ray Escherichia coli/*ENZYMOLOGY Human Kinetics Models, Molecular Molecular Sequence Data Nucleoside-Phosphate Kinase/*CHEMISTRY/*METABOLISM Phosphorylation *Protein Structure, Secondary Saccharomyces cerevisiae/ENZYMOLOGY Sequence Alignment Support, Non-U.S. Gov't Zidovudine/*ANALOGS & DERIVATIVES/METABOLISMKWDjournalarticleaminoacidsequenceantiviralagents/KWDmetabolismcatalyticdomaincrystallography,x-rayescherichiacoli/KWDenzymologyhumankineticsmodels,molecularmolecularsequencedatanucleoside-phosphatekinase/KWDchemistry/KWDmetabolismphosphorylationKWDproteinstructure,secondarysaccharomycescerevisiae/enzymologysequencealignmentsupport,non-uKWDsKWDgov'tzidovudine/KWDanalogs&derivatives/metabolism
990330
A9931034

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .